FRLN
Freeline Therapeutics Holdings plc
1 day chart
About FRLN
Freeline Therapeutics Holdings plc is a United Kingdom-based clinical-stage adeno-associated virus (AAV)-based gene therapy company. The Company’s initial focus is on developing treatments for monogenic diseases with high unmet need. It is engaged in the value chain in gene therapy, including expression platform, research, manufacturing, clinical development and commercialization. The Company’s AAV vector technology cassette is designed to deliver a functional copy of a therapeutic gene into the human liver to offer secretion of the therapeutic protein(s) into the patient’s blood. Therapeutic AAV vectors consist of two main components: the capsid and the expression cassette. The Company’s pipeline includes three programs in the clinic, as well as research programs. Its pipeline includes FLT180a for the Treatment of Hemophilia B, FLT190 for the Treatment of Fabry Disease and FLT201 for the Treatment of Gaucher Disease Type 1.
Buy US stocks in Australia with $0 brokerage and trade FRLN today!
$45.48M
-
0.00%
17.27K
$0.73
$0.65
$0.68
$3.54
$0.65
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.